Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has announced that ImmunoBON, the Group’s patented protein-based oral product for the general treatment of..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has announced the secondary endpoint results from an ex-vivo biomarker study VLP001 which evaluated the Group’s novel virus-like..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore,..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has today announced that it will host a webinar entitled ‘VLP Peanut; a next generation..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has announced positive primary results from an ex-vivo biomarker study evaluating the Group’s novel virus-like particle (VLP) based..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announced its trading update for the year ended 30 June 2021. – Strong 2021 operating profit..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announced that the Group will be sharing key scientific findings from across its research portfolio..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announced a pre-close trading update for the year ended 30th June 2021. The Group plans..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the completion of treatment period of all patients in its exploratory field study..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announced, that following a competitive tender process, BDO LLP has been appointed as its external..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has announced that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, has announced its unaudited interim results for the six months ended 31 December 2020. Highlights Financial..
Shares of Admiral Group with company EPIC: LON:ADM has increased 2.05% or 64 points in today’s trading session so far. Buyers have so far held a positive outlook during this..
The share price for Accrol Group Holdings with ticker code: LON:ACRL has moved up 4.41% or 3 points during the course of today’s session so far. Buyers have so far..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today provided a trading update for the six months ended 31 December 2020 ahead of..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has announced that an ex-vivo biomarker study of blood samples from peanut allergy patients has begun at Imperial College..
Shares in Allergy Therapeutics found using EPIC: LON:AGY has climbed 15.32% or 2.13 points throughout today’s trading session so far. Traders have remained optimistic throughout the session. Range high for..
Shares of Allergy Therapeutics found using EPIC: LON:AGY has increased 10.09% or 1.38 points during the course of today’s session so far. Buyers have remained positive during this period. The..
Stock in Allergy Therapeutics EPIC code: LON:AGY has stepped up 6.37% or 0.81 points during the course of today’s session so far. Investors have remained optimistic while the stock has..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the screening of the first patient in its exploratory field study (G309) to evaluate..
